{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-025946","form_type":"8-K","ticker":"CRMD","cik":"0001410098","company_name":"CorMedix Inc.","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.568595+00:00","generated_at":"2026-06-25T17:59:39.059108+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CorMedix: Q1 net loss $7.0M; FDA accepts DefenCath NDA resubmission with 6-mo review","bullets":["Net loss $7.0M ($0.18/shr) vs $7.2M ($0.20/shr) in Q1 2021; operating expenses down 3%.","FDA accepted DefenCath NDA resubmission as complete Class 2 response with 6-month review; inspection planned.","New CEO Joe Todisco officially started May 10; CCO Tom Nusbickel departed by mutual agreement.","Donna Ucci (SVP Global Quality) and Frank Raffaele (VP Supply Chain) hired; Liz Hurlburt promoted.","Winding down European ops, discontinuing Neutrolin distribution to focus on US DefenCath launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-025946","json":"https://secwatch.observer/filing/0001213900-22-025946.json","markdown":"https://secwatch.observer/filing/0001213900-22-025946.md","text":"https://secwatch.observer/filing/0001213900-22-025946.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1410098/000121390022025946/0001213900-22-025946-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1410098/000121390022025946/ea159840-8k_cormedix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T17:59:39.059108+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}